Last reviewed · How we verify

CE Ferulic

Goldman, Butterwick, Fitzpatrick and Groff · Phase 2 active Small molecule

CE Ferulic is a Small molecule drug developed by Goldman, Butterwick, Fitzpatrick and Groff. It is currently in Phase 2 development for Photoaging and fine lines (cosmetic/anti-aging indication), Skin antioxidant protection.

CE Ferulic is a topical antioxidant serum combining vitamin C, vitamin E, and ferulic acid to neutralize free radicals and protect skin from oxidative damage.

CE Ferulic is a topical antioxidant serum combining vitamin C, vitamin E, and ferulic acid to neutralize free radicals and protect skin from oxidative damage. Used for Photoaging and fine lines (cosmetic/anti-aging indication), Skin antioxidant protection.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameCE Ferulic
SponsorGoldman, Butterwick, Fitzpatrick and Groff
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

The formulation works synergistically: L-ascorbic acid (vitamin C) provides antioxidant protection and collagen synthesis support, vitamin E enhances stability and provides additional antioxidant benefits, and ferulic acid stabilizes the vitamins and amplifies their photoprotective effects. This combination is designed to improve skin texture, reduce signs of aging, and provide photoprotection when used with sunscreen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CE Ferulic

What is CE Ferulic?

CE Ferulic is a Small molecule drug developed by Goldman, Butterwick, Fitzpatrick and Groff, indicated for Photoaging and fine lines (cosmetic/anti-aging indication), Skin antioxidant protection.

How does CE Ferulic work?

CE Ferulic is a topical antioxidant serum combining vitamin C, vitamin E, and ferulic acid to neutralize free radicals and protect skin from oxidative damage.

What is CE Ferulic used for?

CE Ferulic is indicated for Photoaging and fine lines (cosmetic/anti-aging indication), Skin antioxidant protection.

Who makes CE Ferulic?

CE Ferulic is developed by Goldman, Butterwick, Fitzpatrick and Groff (see full Goldman, Butterwick, Fitzpatrick and Groff pipeline at /company/goldman-butterwick-fitzpatrick-and-groff).

What development phase is CE Ferulic in?

CE Ferulic is in Phase 2.

What are the side effects of CE Ferulic?

Common side effects of CE Ferulic include Mild irritation or redness, Sensitivity in patients with vitamin C intolerance.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing